retatrutide clinical trials obesity Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage trial, the company announced. In Eli Lilly's retatrutide shows promising

Partnership with OpenLoop MEDVi relies on OpenLoop for medical infrastructure and clinician oversight

The GRADE assessment rated 24 outcomes (20%) as High, 17 (14%) as Moderate, 25 (21%) as Low, and 52 (44%) as Very Low

To overcome the short half-life and frequent subcutaneous administration of pramlintide, new amylin receptor agonists like cagrilintide have been developed

C., Zaffina, I., Giofr, F., Pujia, R

To evaluate the effects of GLP-1(2836) on cellular bioenergetics, we used the Seahorse extracellular flux analyzer and performed glycolysis stress tests to measure glycolysis and glycolytic capacity and reserve in intact caSMCs

This applies to metformin, glipizide, and all other oral diabetes medications